|  |  |
| --- | --- |
| **Photo**   |  | | --- | | **Dr. KAUSHAL KISHORE**  A multi-faceted professional accustomed with proven management skills; targeting senior-level opportunities in Process Development, Research & Development, Technology Transfer with an organization of high reputed.  **Ph: +91-7981644741 & 9177001933| E-Mail: Kaushal500@yahoo.com** | |
| **Profile Summary**   * **Ph.D. in Synthetic OrganicChemistry** with 24 yearsof experience in managing **aromatic annulations, Heterocyclic and carbocyclic compounds**, complex impurities, natural products synthesis on Chiron & Asymmetric, coordinating with team and enhancing process * Demonstrated competence in executing a **wide gamut of functions such as data management, analytical research**, validation, quality control documentation and co-ordination. * Holding excellent skills in **Parallel Synthesis Equipment** such as Quest, Bhodan Mini Blocks, Savant Speed vac, Combi-flash) and pilot/ manufacturing scale-up reactors, evaporators and filtration modules. * Planned and **organized day-to-day research activities** and resolved the procedural problems as appropriate way to the timely completion of research objectives. * Spearheaded the activities of **setting up, operating and maintaining a variety of laboratory** and/or field research equipment as specified by the requirements of the research study; experience in **cGLP/cGMP and Lab Safety Protocols.** * An **energetic, self-motivated team leader** with hands-on experience in requirements gathering, examination, evaluation and customization.      * Gained in-depth knowledge in:   **Knowledge Purview**   * + Process development of API molecules with an appropriate synthetic routes and reagents uses to make the process robust within the stipulated time.   + Inter-disciplinary subjects like pharmacology, DMPK, molecular modelling and toxicology   + Purification and Characterization of organic compounds by a variety of analytical techniques, flash chromatography, NMR, IR, Mass, and so on   + Performing air-sensitive reactions, reagents and handling chemical reactions like, Lithiation (Metalation), Cynation, Halogenations, Nitration, Grignard, Esterification and Hydrogenation.   + Chemistry programs like Chem-Draw, STN, SCI-FINDER and ACD Labs     **Core Competencies**   |  |  |  | | --- | --- | --- | | Research & Development  Process Development  Consulting & Advisory | New Product Development  Project Planning and Execution  Strategic Management | Quality Analysis  Laboratory Operations  Team Building & Leadership |   **Notable Accomplishments**   * Ensured successful completion of the prestigious Anastrozole, Capecitabine, Letrozole, Decitabine, Bendamustine, Atorvastatin, Cinacalcet Hydrochloride, Mirabegron, Hydroxy Chloroquine Sulphate(HCQ), Favipiravir, Donepezil Hydrochloride(Form-II), Rosuvastatin Calcium, Montelukast Sodiumproject within the approved budget by continuous monitoring of budget movement and optimized the utilization as Project Lead. * Attained the completely indigenous development and commercialization of products like, Ofloxacin, Rosuvastatin Calcium, Montelukast Sodium and Donepezil Hydrochloride Form-III(JP) etc. * Participated in many National & International technology events and product strategy workshops to understand future technology & product needs, some of these included flow-chemistry, Green-chemistry etc. * Received the Best technical initiative award for consecutive two years in 2010 and 2011 and 2013 and 2014 excellence launching awards in DR .Reddy’s.     **Current Work Experience**   * **21st Dec. 2021, onwards working in Enal Drugs, Hyderabad as a General Manager in R&D. Working on API’s as well as New intermediates with cost effective and safety compliance.**   **1stNov’2018 to Dec. 2021: Therapiva, Hyderabad as Deputy General Manager / MSAT Head (R&D, Technology**  **Transfer and Site Investigation)**  **Role:**   * Spearheading the process development of new products like, Mirabegron, Hydroxy chloroquine sulphate from DCQ and HNDA, Favipiravir from DMEA. HCl, Molnupiravir from cytidine and Umifenovir. * Steering efforts in mapping andenhancing the bottle-neck for the capacity enhancement of different products. * Performing investigations on incidents, OOT/OOS and customer complain. * Identifying, collecting, processing, analysing and cataloguing data according to established protocol, procedures & standards, as appropriate to specific objectives of the research study. * Planning and organising day-to-day research activities and resolving procedural problems as an appropriate to the timely completion of research objectives. * Setting up, calibrating, operating and maintaining a variety of laboratory equipment as specified by the requirements of the research study * Characterising all lab prepared compounds, documentation of data, data management, literature updates and report presentations * Ensuring appropriate procedures and standards for the collection and preservation of data are adhered too. * Maintaining a broad knowledge of state-of-the-art research techniques, technology and / or systems * Inspecting the standards and taking the necessary actions for the non-conformities with Customers.   **2009 – 30th Oct.2018: Dr.Reddy’s, Hyderabad (Central Process Innovation Team - API)**  Joined as **Manager**, promoted as **Senior Manager** and then rose to the post of **Associate Director**  **Role:**   * Developed products such as Cinacalcet Hydrochloride, Montelukast Sodium, Doxazosin mesylate, Dimethyl fumarateand Rosuvastatin Calcium. * Followed rubrics template for OOS/OOT failure investigation and introduced appropriate CAPA along with cGMP practice at Site as the Site Investigation Lead * Ensured process robustness of the API products by using DoE and Minitab * Performed five FDA audits in API with some of renowned auditors like, Peter Becker, Depesh Shah and Carlos * Engaged in identifying, isolating, characterizingand structuringelucidation of impurities: synthesis & profiling of API molecules containing intermediates and related impurities in-house for serving to external as well as internal customers. * Reviewed regulatory deficiency within the stipulated time-line for cut-off and doping studies along with TGA and justification report * Reducedtheproduct cost by improving yields, re-cycle solvents, reduction of time-cycle and enhancement of batch size capacity and controlling the effluent load towards green chemistry during the execution. * Vendor/New source qualifying the validation within the spec/protocol * Followed Du-Pont safety guidelines such as PSM, in the site while the batch execution in the Plant * Contributed as the Chairman of QII Committee and Active Member of PSM Committee like (PHA & Toxic) for the products and Member of SOI committee.     **Previous Experience**  **1st Nov.2018 -Dec. 2021: Therapiva Pvt. Ltd. Hyderabad as Deputy General Manager**  **2009 – 2018: Dr. Reddy’s, Hyderabad as Associate Director**  **2007 – 2008: Sai Advantium Pharma Ltd., Hyderabad as Principal Scientist**  **2003 – 2007: Ranbaxy Laboratories Ltd., Gurgaon as Sr. Research Scientist**  **1999 – 2003: Sami Labs Ltd., Bangalore as Research Scientist**  **1993 – 1999: North Eastern-Hill University, location as Senior Research Fellow**    **Education**   * Ph.D. (Synthetic Organic Chemistry) from North Eastern-Hill University in 1999   + Mentor: Prof. H. Ila/H. Junjappa Thesis: New Synthetic Routes to Carbocycles and Heterocycles via α-Oxoketene Dithioacetals * M.Sc. (Organic Chemistry) from Magadh University, Bodhgaya in 1989 * B.Sc. (Chemistry Hons.) from Magadh University, Bodhgaya in 1987     **PUBLICATIONS AND PATENTS**   * Novel Hybrid Molecules of QuinazolineChalcone Derivatives: Synthesis and Study of IN Vitro Cytotoxic Activities; Arun KumarThiriveedhi, Ratnakaram Venkata Nadh, Navuluri Srinivasan and **Kishore Kaushal**. Letters in Drug Design &Discovery: 757-765, 15, 2018. * Novel CoumarinIsoxazoline Derivatives Synthesis and Study of Antibacterial Activities; Suresh, G., R.V. Nadh. Srinivasu, N: **Kaushal, K**. Synthetic Comm. 46(24): 1972-1980, 2016 * Discovery of conformationally rigid 3-azabicyclo [3.1.0] hexane-derived dipeptidyl peptidase-IV inhibitors; JitendraA.Sattigri, Murugaiah M S Andappan, **Kaushal Kishore**, Srinivasan Thangathirupathy, SindujaSundaram, Suchita Sharma, Joseph A. Davis, Anita Chugh, Vinay S. Bansal. Bioorganic & medicinal; Chemistry Letters 2008, Vol. 18, 2008 * Derivatives of Beta-Amino Acid as Dipeptidyl Peptidase-IV Inhibitors; Jitendra A. Sattigeri, Murugaiah M.S. Andappan, Sachin Sethi, Lalima Sharma, Chanchal Kumar Pal, Sachin R Kandalkar, Dipak C Mahajan, **Kaushal Kishore**, Sumati Bhatia, Anil G Gadhave, Vinay S Bansal and Joseph Alexanand Davis. Pat. WO2007/77508 (A2). EP 1973918 (A2) * Process for preparation of (3R, 5R)-7-[2-(4-Flurophenyl)-5-Isopropyl-3-Phenyl-4-[(4-Hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-Dihydroxy-heptanoicacid Hemi Calcium Salt; JitenderaSattegiri, Sachin Sethi, **Kaushal Kishore**. Pat.WO2007/54789 A1, 2007 * Derivatives of 3-Azabicyclo [3.1.0] hexane as Dipeptidyl Peptidase-IV; Jitendra A Sattigeri, MurugaiahAndappan, **Kaushal Kishore**, Sachin Sethi, Sachin R Kandalkar, Chanchal Kumar Pal, Dipak Mahajan, Shahadat Ahmed, Santhosh Sadashiv Parkale, T Srinivasan, Lalima Sharma, Vinay S. Bansal, Anita Chugh and Joseph Alexanand Davis. Pat. WO/2007/029086. EP1931633 (A2) * Pharmaceutical Combination comprising Atorvastatin Derivatives; SattigiriJitendraAnant; Sethi Sachin; **Kaushal Kishore** BR2006PI18381 (A2) * “Derivatives of beta-Amino Acid as Dipeptidyl Peptidase-IV Inhibitors.” Jitendra A. Sattigeri, Murugaiah M.S. Andappan, Sachin Sethi, Lalima Sharma, Chanchal Kumar Pal, Sachin R Kandalkar, Dipak C Mahajan, **Kaushal Kishore**, Sumati Bhatia, Anil G Gadhave, Vinay S Bansal and Joseph Alexanand Davis. Indian Provisional Pat. App. 2005, 3520/DEL/2005 (PCT filed in Dec. 2006) * A Novel Process for the Preparation of (3R, 5R)-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4-[(4-Hydroxy Methyl Phenyl Amino) Carbonyl]-Pyrrol-1-yl]-3,5-Dihydroxy-Heptanoic acid Hemi Calcium Salt; JitenderaSattegiri,SachinSethi, **Kaushal Kishore**. Indian Provisional Pat. App. 2005, 3033/Del/2005 (WO2006IB0315320061108). * Bis-(1-phenyl-5-nitro-6-methylthio-1, 2, 3, 4-tetrahydropyrimidinyl) benzene and Bis-(1-phenyl-5-nitro-6-methylthio-1, 2, 3, 4-tetrahydropyrimidinyl) diphenyl; Milan C.Dutta, Kaushik Chanda, **Kaushal Kishore**, J. N.VishwakarmaMolbank M 428, 2005 * Bis-(1-phenyl-5-nitro-6-methylthio-1,2,3,4-tetrahydropyridiminyl) ethane and Bis-(1-phenyl-5-nitro-6-methylthio-1,2,3,4-tetrahydropyridiminyl) butane; Kaushik Chanda, Milan, C. Dutta, Kaushal Kishore, J. N. Vishwakarma. Mol Bank, M 367, 2004 * A Facile Synthesis of Substituted 1, 2, 3, 4-tetrahydropyrimidines; Enamul Karim; **Kaushal Kishore**; Jai N. Vishwakarma. J. Het. Chem., 4092, 40, 2003. * Preparation of Lithium 5-Lithiomethyl-3-Methylpyrazole-1-Carboxylate and its Reaction with α-Oxoketene Dithioacetals: A New General Method for Substituted and Annealed Pyrazolo [1,5-a] pyridines; **Kaushal Kishore**; Reddy K.R.; Suresh J.R.; H. Ila and H. Junjappa. Tetrahedron, 7645-7652, vol. 55, # 24p. 1999 * A New Class of potential Insecticides and Pesticides Substituted 1, 2, 3, 4-tetrahydropyrimidines; Karim, E; **Kishore, K** and Vishwakarma, J.N., National Seminar on Management Strategies for North Eastern Hilly Ecosystem, India, Abstracts. Aug. 8- 10, p-67, 1998     **Personal Details**  Date of Birth: 31.12.1965  Address: Hyderabad-500014, India  Languages: English and Hindi. |
|  |